Compare Sanofi SA (SNY) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Invesco Solar ETF — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Invesco Solar ETF trades at $53.51. The key difference: Sanofi SA pays a 5.5% dividend while Invesco Solar ETF pays none, and Invesco Solar ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | TAN | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | Sector/Thematic |
52-Week High | $52.34 | $73.95 |
52-Week Low | $41.33 | $36.07 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
TAN trades at $52.69, down 2.24% amid broad market weakness, with technical indicators signaling a bearish trend. The ETF faces headwinds from lower oil prices and a strong US dollar, though long-term growth prospects remain tied to rising electricity demand from data centers and AI. Recent news highlights both opportunities in the energy transition and risks from regulatory delays and geopolitical tensions affecting solar investments.
The outlook for TAN is cautious near-term due to technical deterioration and valuation concerns, but sustained demand for clean energy offers long-term potential. Key risks include policy uncertainty, competition from nuclear energy, and reliance on large-scale solar projects. Investors should weigh volatility against the structural shift toward renewable infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
